Literature DB >> 32176361

Potentially repurposing adamantanes for COVID-19.

Nevio Cimolai1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32176361     DOI: 10.1002/jmv.25752

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


× No keyword cloud information.
  12 in total

Review 1.  Loop-Mediated Isothermal Amplification Detection of SARS-CoV-2 and Myriad Other Applications.

Authors:  Keith J M Moore; Jeremy Cahill; Guy Aidelberg; Rachel Aronoff; Ali Bektaş; Daniela Bezdan; Daniel J Butler; Sridar V Chittur; Martin Codyre; Fernan Federici; Nathan A Tanner; Scott W Tighe; Randy True; Sarah B Ware; Anne L Wyllie; Evan E Afshin; Andres Bendesky; Connie B Chang; Richard Dela Rosa; Eran Elhaik; David Erickson; Andrew S Goldsborough; George Grills; Kathrin Hadasch; Andrew Hayden; Seong-Young Her; Julie A Karl; Chang Hee Kim; Alison J Kriegel; Thomas Kunstman; Zeph Landau; Kevin Land; Bradley W Langhorst; Ariel B Lindner; Benjamin E Mayer; Lee A McLaughlin; Matthew T McLaughlin; Jenny Molloy; Christopher Mozsary; Jerry L Nadler; Melinee D'Silva; David Ng; David H O'Connor; Jerry E Ongerth; Olayinka Osuolale; Ana Pinharanda; Dennis Plenker; Ravi Ranjan; Michael Rosbash; Assaf Rotem; Jacob Segarra; Stephan Schürer; Scott Sherrill-Mix; Helena Solo-Gabriele; Shaina To; Merly C Vogt; Albert D Yu; Christopher E Mason
Journal:  J Biomol Tech       Date:  2021-09

2.  Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment.

Authors:  Konrad Rejdak; Paweł Grieb
Journal:  Mult Scler Relat Disord       Date:  2020-04-30       Impact factor: 4.339

3.  In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors.

Authors:  Mahmoud A A Ibrahim; Alaa H M Abdelrahman; Khaled S Allemailem; Ahmad Almatroudi; Mahmoud F Moustafa; Mohamed-Elamir F Hegazy
Journal:  Protein J       Date:  2021-01-02       Impact factor: 4.000

4.  Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2.

Authors:  Albert Cortés-Borra; Gonzalo Emiliano Aranda-Abreu
Journal:  Pharmacol Rep       Date:  2021-02-18       Impact factor: 3.024

5.  Aminoglycosides and their potential as SARS-CoV-2 antivirals.

Authors:  Nevio Cimolai
Journal:  Med Hypotheses       Date:  2021-03-23       Impact factor: 1.538

Review 6.  Antivirals for COVID-19: A critical review.

Authors:  Andri Frediansyah; Ruchi Tiwari; Khan Sharun; Kuldeep Dhama; Harapan Harapan
Journal:  Clin Epidemiol Glob Health       Date:  2020-07-28

7.  Synthesis, structure, and antiviral properties of novel 2-adamantyl-5-aryl-2H-tetrazoles.

Authors:  Olga V Mikolaichuk; Vladimir V Zarubaev; Anna А Muryleva; Yana L Esaulkova; Daria V Spasibenko; Alina А Batyrenko; Ilya V Kornyakov; Rostislav Е Trifonov
Journal:  Chem Heterocycl Compd (N Y)       Date:  2021-05-26       Impact factor: 1.277

Review 8.  Potential for the Repurposing of Adamantane Antivirals for COVID-19.

Authors:  Roger F Butterworth
Journal:  Drugs R D       Date:  2021-06-21

9.  A retrospective review of memantine use and COVID-19-associated mortality from a national database.

Authors:  Moon Ho Park; Do Young Kwon
Journal:  J Med Virol       Date:  2020-07-14       Impact factor: 20.693

Review 10.  Neurological manifestations and neuro-invasive mechanisms of the severe acute respiratory syndrome coronavirus type 2.

Authors:  K Vonck; I Garrez; V De Herdt; D Hemelsoet; G Laureys; R Raedt; P Boon
Journal:  Eur J Neurol       Date:  2020-06-16       Impact factor: 6.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.